Incretin Analog Dosing and Composition Methods for GLP-1 GIP GCG Tri-Agonists
Summary
The USPTO published patent application US20260091088A1 disclosing dosing regimens and compositions for long-acting incretin analogs comprising glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon (GCG) tri-receptor agonists suitable for once-weekly administration. The application covers methods for treating metabolic conditions including obesity (A61P 3/04) and diabetes (A61P 3/10).
What changed
The USPTO published a patent application (US20260091088A1) for incretin analog compositions and dosing methods targeting GLP-1, GIP, and GCG receptors. The application discloses long-acting formulations suitable for weekly dosing for metabolic disorders. Inventors include Tamer Coskun, Zvonko Milicevic, and Shweta Urva, with Application No. 19393216 filed November 18, 2025.
This is a patent publication notice with no compliance requirements or deadlines. Pharmaceutical companies and researchers in the metabolic therapy space may review the application to understand the competitive landscape or freedom-to-operate considerations. No regulatory action is required.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
METHODS OF USING AND COMPOSITIONS INCLUDING AN INCRETIN ANALOG
Application US20260091088A1 Kind: A1 Apr 02, 2026
Inventors
Tamer COSKUN, Zvonko MILICEVIC, Shweta URVA
Abstract
Doses and dosing regimens for incretin analogs are disclosed comprising determining and administering doses of long-acting incretin analogs suitable for once-weekly dosing, such as a glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) (GGG) tri-receptor agonist.
CPC Classifications
A61K 38/26 A61P 3/04 A61P 3/10
Filing Date
2025-11-18
Application No.
19393216
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.